Movement Alert｜Hengrui Medicine Falls 3.11% in Regular Trading, Policy Headwinds Continue to Pressure Innovative Drug Stocks

Market Focus06-04 10:14

On June 4, Hengrui Medicine (01276.HK) declined 3.11% in regular trading, trading at HK$52.95/share, with trading volume of HK$122 million. The stock continues to face selling pressure amid unresolved dual policy overhang from both Chinese and U.S. regulatory fronts.

The decline extends a multi-week downturn triggered by a circulating draft revision to China's prohibited/restricted technology export list, which proposes classifying core platform technologies in bispecific antibodies, ADCs, PROTAC, and siRNA as restricted or prohibited for outbound transfer. Simultaneously, the U.S. House China Select Committee has pushed to include biotechnology in the COINS Act, explicitly targeting BD licensing deals and naming Hengrui's collaboration with BMS. While Hengrui's Co-Co model with BMS does not involve platform ownership transfer and the company has stated operations remain normal, the persistent policy uncertainty continues to weigh on sentiment across the innovative pharma sector. Within the Pharmaceuticals sector, LUYE PHARMA fell 11.98%, CMS declined 0.84%, CSPC PHARMA dropped 0.83%, SBP GROUP lost 1.68%, and HANSOH PHARMA dipped 0.33%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133277267?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133277267","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Falls 3.11% in Regular Trading, Policy Headwinds Continue to Pressure Innovative Drug Stocks","media":"Market Focus","content":"<p><p>On June 4, Hengrui Medicine (01276.HK) declined 3.11% in regular trading, trading at HK$52.95/share, with trading volume of HK$122 million. The stock continues to face selling pressure amid unresolved dual policy overhang from both Chinese and U.S. regulatory fronts.</p><p>The decline extends a multi-week downturn triggered by a circulating draft revision to China's prohibited/restricted technology export list, which proposes classifying core platform technologies in bispecific antibodies, ADCs, PROTAC, and siRNA as restricted or prohibited for outbound transfer. Simultaneously, the U.S. House China Select Committee has pushed to include biotechnology in the COINS Act, explicitly targeting BD licensing deals and naming Hengrui's collaboration with BMS. While Hengrui's Co-Co model with BMS does not involve platform ownership transfer and the company has stated operations remain normal, the persistent policy uncertainty continues to weigh on sentiment across the innovative pharma sector. Within the Pharmaceuticals sector, LUYE PHARMA fell 11.98%, CMS declined 0.84%, CSPC PHARMA dropped 0.83%, SBP GROUP lost 1.68%, and HANSOH PHARMA dipped 0.33%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Falls 3.11% in Regular Trading, Policy Headwinds Continue to Pressure Innovative Drug Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Falls 3.11% in Regular Trading, Policy Headwinds Continue to Pressure Innovative Drug Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Hengrui Medicine (01276.HK) declined 3.11% in regular trading, trading at HK$52.95/share, with trading volume of HK$122 million. The stock continues to face selling pressure amid unresolved dual policy overhang from both Chinese and U.S. regulatory fronts.</p><p>The decline extends a multi-week downturn triggered by a circulating draft revision to China's prohibited/restricted technology export list, which proposes classifying core platform technologies in bispecific antibodies, ADCs, PROTAC, and siRNA as restricted or prohibited for outbound transfer. Simultaneously, the U.S. House China Select Committee has pushed to include biotechnology in the COINS Act, explicitly targeting BD licensing deals and naming Hengrui's collaboration with BMS. While Hengrui's Co-Co model with BMS does not involve platform ownership transfer and the company has stated operations remain normal, the persistent policy uncertainty continues to weigh on sentiment across the innovative pharma sector. Within the Pharmaceuticals sector, LUYE PHARMA fell 11.98%, CMS declined 0.84%, CSPC PHARMA dropped 0.83%, SBP GROUP lost 1.68%, and HANSOH PHARMA dipped 0.33%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1133277267","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133277267","pubTimestamp":1780539278,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Hengrui Medicine (01276.HK) declined 3.11% in regular trading, trading at HK$52.95/share, with trading volume of HK$122 million. The stock continues to face selling pressure amid...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动感快讯|恒瑞医药常规交易跌3.11%政策逆风持续打压创新药股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On June 4, Hengrui Medicine (01276.HK) declined 3.11% in regular trading, trading at HK$52.95/share, with trading volume of HK$122 million. The stock continues to face selling pressure amid unresolved dual policy overhang from both Chinese and U.S. regulatory fronts.The decline extends a multi-week downturn triggered by a circulating draft revision to China's prohibited/restricted technology export list, which proposes classifying core platform technologies in bispecific antibodies, ADCs, PROTAC, and siRNA as restricted or prohibited for outbound transfer. Simultaneously, the U.S. House China Select Committee has pushed to include biotechnology in the COINS Act, explicitly targeting BD licensing deals and naming Hengrui's collaboration with BMS. While Hengrui's Co-Co model with BMS does not involve platform ownership transfer and the company has stated operations remain normal, the persistent policy uncertainty continues to weigh on sentiment across the innovative pharma sector. Within the Pharmaceuticals sector, LUYE PHARMA fell 11.98%, CMS declined 0.84%, CSPC PHARMA dropped 0.83%, SBP GROUP lost 1.68%, and HANSOH PHARMA dipped 0.33%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133277267","isCrawlerRequest":true}